Analyzing clinical results of dexamethasone implant effect on macular thickness
Publication
Video
Modern Retina Digital EditionModern Retina Summer 2021
Volume 1
Issue 1
Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
Daniel F. Kiernan, MD, a vitreoretinal surgeon at The Eye Associates, Sarasota, Florida, discusses the highlights of his 2021 ARVO virtual presentation on the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on optical coherence tomography (OCT) testing following vitreoretinal surgery.
Articles in this issue
Sustained-release anti-inflammatory therapy is valuable in noninfectious uveitis
Pediatric ophthalmologists target inherited retinal diseases
Gaining a greater understanding of AMD
VEGF and beyond: therapeutic targeting in retinal vascular disorders
Laser imaging system may offer early detection, treatment for eye diseases that cause blindness
Analyzing clinical results of dexamethasone implant effect on macular thickness
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Recent Videos
Related Content
